These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38498227)

  • 1. Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes.
    Della Pepa G; Lupoli R; Masulli M; Boccia R; De Angelis R; Gianfrancesco S; Piccolo R; Rainone C; Rivellese AA; Annuzzi G; Bozzetto L
    J Endocrinol Invest; 2024 Sep; 47(9):2371-2378. PubMed ID: 38498227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes.
    Aernouts C; Beldé SPW; Lambrechts J; Mertens J; Ledeganck KJ; Francque SM; De Block CEM
    Diabetes Obes Metab; 2024 Sep; 26(9):3781-3790. PubMed ID: 38924290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes.
    Sviklāne L; Olmane E; Dzērve Z; Kupčs K; Pīrāgs V; Sokolovska J
    J Gastroenterol Hepatol; 2018 Jan; 33(1):270-276. PubMed ID: 28464337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity.
    De Nucci S; Bonfiglio C; Donvito R; Di Chito M; Cerabino N; Rinaldi R; Sila A; Shahini E; Giannuzzi V; Pesole PL; Coletta S; Lanzilotta E; Piazzolla G; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2023 Oct; 15(20):. PubMed ID: 37892542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive Indices of MASLD Are Associated With Hypogonadism in Male Patients With Type 2 Diabetes Mellitus.
    Caretta N; Scafa R; Graziani A; Crepaldi MC; Vedovato M; Avogaro A; Ferlin A
    J Clin Endocrinol Metab; 2024 Jan; 109(2):e522-e530. PubMed ID: 37795977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the clinical value of five noninvasive predictors of metabolic dysfunction-associated steatotic liver disease in Han Chinese adults.
    Ma X; Zou H; Zhan J; Gao J; Xie Y
    Eur J Gastroenterol Hepatol; 2024 Oct; 36(10):1209-1219. PubMed ID: 38973526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poorly controlled pediatric type 1 diabetes mellitus is a risk factor for metabolic dysfunction associated steatotic liver disease (MASLD): An observational study.
    Koutny F; Wiemann D; Eckert A; Meyhöfer S; Fritsch M; Pappa A; Wiegand S; Weyer M; Wurm M; Weghuber D; Holl RW
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1027-1037. PubMed ID: 38558281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
    Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
    Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
    Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes.
    Wang C; Cai Z; Deng X; Li H; Zhao Z; Guo C; Zhang P; Li L; Gu T; Yang L; Zhao L; Wang D; Yuan G
    Int J Med Sci; 2021; 18(14):3280-3289. PubMed ID: 34400897
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.
    Kjeldsen SAS; Werge MP; Grandt J; Richter MM; Thing M; Hetland LE; Rashu EB; Jensen AH; Winther-Sørensen M; Kellemann JS; Holst JJ; Junker AE; Serizawa RR; Vyberg M; Gluud LL; Wewer Albrechtsen NJ
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G558-G570. PubMed ID: 39104323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease.
    Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Ng CH; Siddiqui MS; Fukao T; Shimizu M; Yamamoto M
    JGH Open; 2024 Jun; 8(6):e13110. PubMed ID: 38895100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.
    Chen Q; Hu P; Hou X; Sun Y; Jiao M; Peng L; Dai Z; Yin X; Liu R; Li Y; Zhu C
    Cardiovasc Diabetol; 2024 Jul; 23(1):232. PubMed ID: 38965572
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Rao AS; Hegde S; Pacioretty LM; DeBenedetto J; Babish JG
    J Med Food; 2020 Sep; 23(9):905-919. PubMed ID: 32758056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated steatotic liver disease and risk of esophageal cancer in patients with diabetes mellitus: a nationwide cohort study.
    Jeon YJ; Han K; Lee SW; Lee JE; Park J; Cho IY; Cho JH; Shin DW
    Dis Esophagus; 2024 Jul; 37(8):. PubMed ID: 38587429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic control metrics and metabolic dysfunction-associated steatotic liver disease in children and adolescents with type 1 diabetes.
    Maffeis C; Piona C; Morandi A; Marigliano M; Morotti E; Mancioppi V; Caiazza E; Zusi C; Emiliani F; Mantovani A; Colecchia A; Targher G
    Diabetes Obes Metab; 2024 Dec; 26(12):5896-5905. PubMed ID: 39344839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated LDL-c may warn of the risk of gallbladder stones in the patients with metabolic dysfunction-associated steatotic liver disease: A case-control study.
    Zhao G; Shi R; Ma M; Lin H; Zhang J; Sheng B
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102363. PubMed ID: 38703815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater hepatic lipid saturation is associated with impaired glycaemic regulation in men with metabolic dysfunction-associated steatotic liver disease but is not altered by 6 weeks of exercise training.
    Willis SA; Malaikah S; Bawden SJ; Sherry AP; Sargeant JA; Coull NA; Bradley CR; Rowlands A; Naim I; Ennequin G; Yates T; Waheed G; Gowland P; Stensel DJ; Webb DR; Davies MJ; Aithal GP; King JA
    Diabetes Obes Metab; 2024 Sep; 26(9):4030-4042. PubMed ID: 38978184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Obesity and Metabolic Health Status on Metabolic-Associated Steatotic Liver Disease among Renal Transplant Recipients Using Hepatic Steatosis Index.
    Lin IH; Yu YP; Duong TV; Nien SW; Tseng IH; Wu YM; Chiang YJ; Chiang CY; Chiu CH; Wang MH; Yang NC; Wu TH; Wong TC
    Nutrients; 2024 Oct; 16(19):. PubMed ID: 39408311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.